Hanneke Schuitemaker is the Global Head of Viral Vaccine Discovery and Translational Medicine and the Disease Area Stronghold Leader for Viral Vaccines in Janssen Vaccines and Prevention. In addition, she has been a Professor in Virology at the Amsterdam University Medical Center since 2004.

Hanneke worked for 20+ years in academia on the pathogenesis of HIV infection and co-authored close to 300 peer reviewed scientific publications. In her current position, she is responsible for the port-folio of viral vaccine programs. Most advanced programs in that port-folio are prophylactic and/or therapeutic vaccine candidates for HIV, RSV, Multivalent filo, Ebola, sIPV, Zika and HPV.

During the COVID-19 pandemic Janssen looked to develop a COVID-19 vaccine. Their approach started with a single viral genome, which was being tested as of March 2020.The US regulator FDA approved the Johnson & Johnson Covid-19 vaccine for use on February 27, 2021. Approval by the European Medicines Agency was given on March 11.

Healthcare, Innovation, Technology, Science, COVID-19 Epidemics & Pandemics, Pharmaceutical, Medicine, Research & Exploration, Health, Leadership, Female Leadership, Influential Women, Public Health,